The introduction of HIF-2α inhibitors, such as belzutifan, represents a paradigm shift in the medical management of VHL-associated tumors, offering a noninvasive alternative to surgery for small tumors and demonstrating significant efficacy in reducing tumor burden (12). Here, EPAS1 is linked to neoplasm.